Doxycycline is generally the first-line treatment for Lyme disease. It’s well-tolerated and highly effective in early stages. Amoxicillin provides a similar efficacy profile and is often preferred for pregnant women and children.
Levaquin (levofloxacin), a fluoroquinolone, demonstrates activity against Borrelia burgdorferi, the Lyme disease bacterium. However, it’s typically reserved for cases unresponsive to first-line antibiotics or for patients with contraindications to doxycycline or amoxicillin. This is due to its potential for serious side effects, including tendon damage and peripheral neuropathy, which outweigh the benefits in uncomplicated cases.
Clinical trials directly comparing Levaquin to doxycycline or amoxicillin for early Lyme disease are limited. Existing data suggest similar eradication rates for early Lyme disease with these antibiotics, but Levaquin’s side effect profile makes it a less desirable option initially.
For late-stage Lyme disease (with neurological or joint involvement), the choice of antibiotic depends on the specific manifestation. While Levaquin might be considered in some circumstances, treatment often involves longer courses of ceftriaxone or doxycycline.
Always consult with a physician for diagnosis and treatment of Lyme disease. They will consider your individual medical history and the specifics of your case to choose the most appropriate antibiotic.
